Illumina (NASDAQ:ILMN) Stock Rating Cut to “Equal Weight” at Stephens

Illumina (NASDAQ:ILMN) was downgraded by investment analysts at Stephens from an “overweight” rating to an “equal weight” rating in a research note issued to investors on Friday, Marketbeat reports. They currently have a $275.00 target price on the life sciences company’s stock. Stephens‘s target price would indicate a potential upside of 2.07% from the company’s current price.

Several other research analysts also recently issued reports on the stock. Canaccord Genuity Group boosted their price objective on shares of Illumina from $205.00 to $300.00 and gave the stock a “hold” rating in a report on Monday, October 19th. Stifel Nicolaus upped their price target on shares of Illumina from $155.00 to $225.00 and gave the company a “buy” rating in a research note on Friday, July 31st. Citigroup boosted their price target on Illumina from $95.00 to $113.00 and gave the company a “sell” rating in a research note on Monday, August 3rd. Barclays boosted their target price on shares of Illumina from $160.00 to $200.00 and gave the stock an “underweight” rating in a report on Wednesday, October 7th. Finally, Leerink Partners raised their price objective on shares of Illumina from $220.00 to $300.00 and gave the company an “outperform” rating in a research note on Tuesday, September 29th. Ten equities research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $234.41.

Illumina Price Performance

Illumina stock traded up $0.02 during midday trading on Friday, reaching $269.42. 1,262,784 shares of the company were exchanged, compared to its average volume of 2,685,421. Illumina has a 1 year low of $94.00 and a 1 year high of $309.35. The firm’s 50-day simple moving average is $242.35 and its 200-day simple moving average is $191.10. The company has a market capitalization of $40.68 billion, a price-to-earnings ratio of 50.26, a P/E/G ratio of 3.82 and a beta of 1.41. The company has a debt-to-equity ratio of 0.53, a quick ratio of 1.40 and a current ratio of 1.80.

Illumina (NASDAQ:ILMN) last issued its earnings results on Thursday, July 30th. The life sciences company reported $1.31 earnings per share for the quarter, topping the consensus estimate of $1.23 by $0.08. Illumina had a return on equity of 29.84% and a net margin of 18.36%. The business had revenue of $1.16 billion for the quarter, compared to analyst estimates of $1.13 billion. During the same period last year, the company posted $1.19 EPS. The business’s quarterly revenue was up 9.4% on a year-over-year basis. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. On average, analysts anticipate that Illumina will post 5.36 EPS for the current year.

Insider Buying and Selling at Illumina

In related news, Director Keith Meister sold 119,501 shares of the business’s stock in a transaction that occurred on Friday, September 4th. The shares were sold at an average price of $218.40, for a total value of $26,099,018.40. Following the completion of the transaction, the director owned 770,350 shares of the company’s stock, valued at $168,244,440. The trade was a 13.43% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, SVP Christensen Wedel sold 1,033 shares of the stock in a transaction dated Tuesday, August 18th. The stock was sold at an average price of $191.52, for a total value of $197,840.16. Following the sale, the senior vice president directly owned 14,023 shares in the company, valued at $2,685,684.96. This represents a 6.86% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 2,061,850 shares of company stock worth $436,479,102. Insiders own 2.90% of the company’s stock.

Institutional Investors Weigh In On Illumina

Several institutional investors and hedge funds have recently modified their holdings of the stock. BlackRock Inc. acquired a new stake in Illumina in the second quarter valued at $3,374,423,000. WCM Investment Management LLC boosted its position in shares of Illumina by 45.5% in the first quarter. WCM Investment Management LLC now owns 5,923,173 shares of the life sciences company’s stock worth $715,579,000 after purchasing an additional 1,851,848 shares during the period. Primecap Management Co. CA purchased a new stake in Illumina during the second quarter valued at $617,981,000. Ninety One UK Ltd lifted its holdings in shares of Illumina by 37,920.0% in the 3rd quarter. Ninety One UK Ltd now owns 1,359,974 shares of the life sciences company’s stock worth $372,198,000 after buying an additional 1,356,397 shares during the period. Finally, Jupiter Topco LLC purchased a new stake in Illumina in the second quarter valued at approximately $358,652,000. Hedge funds and other institutional investors own 89.42% of the company’s stock.

More Illumina News

Here are the key news stories impacting Illumina this week:

• Positive Sentiment: Illumina’s upcoming quarterly report could benefit from strong clinical demand, NovaSeq X adoption, new instrument placements, and consumables growth. Analysts also expect year-over-year earnings growth and see potential for an earnings beat, although research-market weakness remains a concern. ILMN Q3 Earnings Preview: Strong Clinical Demand May Lift Performance
• Positive Sentiment: The company launched three early-access capabilities for its BioInsight Platform—Workflow Orchestrator, DRAGEN Ultra with dnaAI, and Learning Cohorts. The tools expand Illumina’s AI-driven variant prioritization, sequencing analysis, and genomic-data workflow offerings, potentially increasing the strategic importance of software and data services. How Investors May Respond To Illumina BioInsight AI Rollout
• Neutral Sentiment: Illumina is expected to report quarterly results next week. The event is a major near-term catalyst, with investor attention likely centered on clinical demand, NovaSeq X placements, consumables revenue, and management’s outlook. Illumina Expected to Release Quarterly Earnings on Thursday
• Neutral Sentiment: The consensus price target was raised 19.65% to $250.77, signaling improved analyst expectations, but that target remains below Illumina’s recent trading level and may limit upside if not revised further. Illumina Consensus Price Target Increased
• Negative Sentiment: Stephens downgraded Illumina to Equal Weight, reducing a potential source of buying pressure and reflecting a more cautious view of the stock’s risk-reward profile. Stephens Downgrades Illumina to Equal Weight
• Negative Sentiment: Illumina recently fell alongside Twist Bioscience and other AI- and genomics-related stocks in a broad technology selloff, indicating that sector sentiment—not company-specific news—has also been driving volatility. Twist Bioscience and Illumina Slide as AI and Genomics Stocks Sell Off

About Illumina

Illumina, Inc is a biotechnology company that develops and manufactures genomics and genetic-analysis technologies. Its products are used to study DNA and RNA in applications including biomedical research, clinical testing, pharmaceutical development, reproductive health, oncology and population genomics.

The company’s offerings include next-generation sequencing systems, consumable flow cells and reagent kits, microarrays, and genomic data-analysis software. Its sequencing portfolio includes instruments such as the NovaSeq, NextSeq, MiSeq and iSeq platforms, while its informatics products include the DRAGEN platform, which supports the processing and interpretation of sequencing data.